- Home
- HFRO vs VNDA Comparison
HFRO vs VNDA Comparison
Compare HFRO & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HFRO
- VNDA
- Stock Information
- Founded
- HFRO 2000
- VNDA 2002
- Country
- HFRO United States
- VNDA United States
- Employees
- HFRO N/A
- VNDA N/A
- Industry
- HFRO Finance/Investors Services
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- HFRO Finance
- VNDA Health Care
- Exchange
- HFRO Nasdaq
- VNDA Nasdaq
- Market Cap
- HFRO 287.7M
- VNDA 286.4M
- IPO Year
- HFRO N/A
- VNDA 2006
- Fundamental
- Price
- HFRO $5.23
- VNDA $4.74
- Analyst Decision
- HFRO
- VNDA Strong Buy
- Analyst Count
- HFRO 0
- VNDA 3
- Target Price
- HFRO N/A
- VNDA $15.33
- AVG Volume (30 Days)
- HFRO 179.8K
- VNDA 474.8K
- Earning Date
- HFRO 01-01-0001
- VNDA 07-31-2025
- Dividend Yield
- HFRO 8.87%
- VNDA N/A
- EPS Growth
- HFRO N/A
- VNDA N/A
- EPS
- HFRO N/A
- VNDA N/A
- Revenue
- HFRO N/A
- VNDA $201,351,000.00
- Revenue This Year
- HFRO N/A
- VNDA $16.86
- Revenue Next Year
- HFRO N/A
- VNDA $39.78
- P/E Ratio
- HFRO N/A
- VNDA N/A
- Revenue Growth
- HFRO N/A
- VNDA 13.37
- 52 Week Low
- HFRO $4.24
- VNDA $3.81
- 52 Week High
- HFRO $6.45
- VNDA $6.34
- Technical
- Relative Strength Index (RSI)
- HFRO 51.63
- VNDA 50.12
- Support Level
- HFRO $5.19
- VNDA $4.60
- Resistance Level
- HFRO $5.25
- VNDA $4.95
- Average True Range (ATR)
- HFRO 0.08
- VNDA 0.19
- MACD
- HFRO -0.01
- VNDA -0.03
- Stochastic Oscillator
- HFRO 69.64
- VNDA 26.92
About HFRO Highland Opportunities and Income Fund of Beneficial Interest
Highland Opportunities and Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to Income Fund seeks growth of capital along with income. It focuses on making investments in real estate securities, including Reits, secured and unsecured fixed-rate loans and corporate bonds, mezzanine securities, structured products, convertible and preferred securities and equities (public and private), and floating rate securities.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.